A review on disease modifying pharmacologic therapies for sickle cell disease.

This prospective study demonstrated a highly significant reduction in the annual rates of painful crises in the patients treated with hydroxyurea compared to the placebo group (2.5 vs. 4.5 painful crises/year, P < 0.001) and thus was terminated early [ 17 ].

also in 132,142 other papers